a nonsignificant trendP = .068
Although there was a nonsignificant trend toward patients with lymph node-only disease receiving LRT in higher proportion (37% vs. 21.5%; P = .068), no differences were observed in patients with visceral (22.7% vs. 26.7%; P = .725) or bone-only (28.7% vs. 20.5%; P = .125) metastases.